GENinCode (LSE:GENI), the genetic testing company focused on cardiovascular disease and ovarian cancer risk, is in focus after interim results published on 29 September 2026 showed lower first-half revenue, a smaller loss and a cash runway the company now expects to extend into the first quarter of 2027. The update also pushed back key milestones, including the timing of a US regulatory filing for its coronary artery disease test and a commercial launch with Thermo Fisher Scientific. Recent market data showed the shares trading at well below one penny.
What the Company Does
GENinCode develops polygenic and genetic risk assessment tests aimed at the prevention of cardiovascular disease, including the CARDIO inCode-Score coronary artery disease polygenic risk score and LIPID inCode for familial hypercholesterolaemia. It also offers ROCA, an ovarian cancer risk algorithm. The group operates in the UK, Spain and the US, where it has been onboarding clinics and institutions.
Latest Developments
For the six months to 30 June 2026, Revenue fell to about £1.13m from £1.60m, with most sales generated in Spain and UK revenue sharply lower. The company attributed the UK decline to NHS cutbacks, funding and strategic changes, and reduced LIPID inCode testing, adding that discussions on reinstatement were continuing. Gross Margin slipped to 47.5% from 53.0%, while the adjusted EBITDA loss narrowed to £2.26m from £2.54m and the loss after tax reduced to £2.52m.
On regulation, GENinCode now expects to finalise its FDA De Novo filing for CARDIO inCode-Score in November 2026, after clinical validation by Kaiser Permanente was completed. In June it had pointed to a third-quarter submission. An EU IVDR filing is expected in December. Thermo Fisher has completed manufacture and clinical validation of the test, but the company said commercial discussions with reference laboratories were slower than expected, with the launch now anticipated later in the year.
On 28 August 2026, preliminary results from a real-world pilot run by the Catalan health service were presented at the ESC Congress in Munich. Among 584 moderate-risk patients, genetic information changed the risk assessment for 42.6%, and average cardiovascular risk and LDL cholesterol fell during follow-up. The company stressed the findings were preliminary.
Financial Picture
For 2025, published on 8 June 2026, revenue rose 14% to £3.1m but the loss for the year widened to £5.7m, and year-end cash was just £0.8m. The shares fell more than 18% to 0.94p that day. In February 2026 the company raised £4.66m gross at 1p per share, lifting cash to £1.98m at 30 June. Revenue guidance for 2026 is now about £3.2m. No Dividend is paid.
Sector and index Context
GENinCode is one of a number of small diagnostics businesses within the FTSE AIM All Share Index whose valuations depend heavily on regulatory approvals, reimbursement and distribution partnerships. Polygenic risk scores are gaining recognition, and the company has noted their inclusion in US primary prevention guidelines.
Key Risks
The most immediate risk is funding: with a short stated runway, further Capital raising appears likely and could dilute shareholders. Delays in FDA clearance, the Thermo Fisher launch or NHS contracts would weigh on revenue, and reliance on Spanish revenue adds concentration risk.
What to Watch Next
Investors will be watching for the FDA De Novo submission in November, the EU IVDR filing in December, confirmation of a commercial launch with Thermo Fisher, any reinstatement of NHS testing and the company's plans for funding beyond the first quarter of 2027.



_11_18_2026_06_43_20_247880.jpg)


Please wait processing your request...